journal
Journals American Journal of Medical Ge...

American Journal of Medical Genetics. Part C, Seminars in Medical Genetics

https://read.qxmd.com/read/36896471/col1a1-and-col1a2-variants-in-ehlers-danlos-syndrome-phenotypes-and-col1-related-overlap-disorder
#1
JOURNAL ARTICLE
Elise Venable, Dacre R T Knight, Emily K Thoreson, Linnea M Baudhuin
Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively). Here we describe a cohort of 34 individuals with likely pathogenic and pathogenic variants in COL1A1 and COL1A2, 15 of whom have potential OIEDS1 (n = 5) or OIEDS2 (n = 10). A predominant OI phenotype and COL1A1 frameshift variants are present in 4/5 cases with potential OIEDS1. On the other hand, 9/10 potential OIEDS2 cases have a predominant EDS phenotype, including four with an initial diagnosis of hypermobile EDS (hEDS)...
March 9, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36864710/gene-targeted-therapies-overview-and-implications
#2
JOURNAL ARTICLE
P J Brooks, Tiina K Urv, Melissa A Parisi
Gene-targeted therapies (GTTs) are therapeutic platforms that are in principle applicable to large numbers of monogenic diseases. The rapid development and implementation of GTTs have profound implications for rare monogenic disease therapy development. This article provides a brief summary of the primary types of GTTs and a brief overview of the current state of the science. It also serves as a primer for the articles in this special issue.
March 2, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36854952/a-review-of-economic-issues-for-gene-targeted-therapies-value-affordability-and-access
#3
JOURNAL ARTICLE
Louis P Garrison, Andrew W Lo, Richard S Finkel, Patricia A Deverka
The National Center for Advancing Translational Sciences' virtual 2021 conference on gene-targeted therapies (GTTs) encouraged multidisciplinary dialogue on a wide range of GTT topic areas. Each of three parallel working groups included social scientists and clinical scientists, and the three major sessions included a presentation on economic issues related to their focus area. These experts also coordinated their efforts across the three groups. The economics-related presentations covered three areas with some overlap: (1) value assessment, uncertainty, and dynamic efficiency; (2) affordability, pricing, and financing; and (3) evidence generation, coverage, and access...
February 28, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36751120/privacy-bias-and-the-clinical-use-of-facial-recognition-technology-a-survey-of-genetics-professionals
#4
JOURNAL ARTICLE
Elias Aboujaoude, Janice Light, Julia E H Brown, W John Boscardin, Benedikt Hallgrímsson, Ophir D Klein
Facial recognition technology (FRT) has been adopted as a precision medicine tool. The medical genetics field highlights both the clinical potential and privacy risks of this technology, putting the discipline at the forefront of a new digital privacy debate. Investigating how geneticists perceive the privacy concerns surrounding FRT can help shape the evolution and regulation of the field, and provide lessons for medicine and research more broadly. Five hundred and sixty-two genetics clinicians and researchers were approached to fill out a survey, 105 responded, and 80% of these completed...
February 7, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36738469/moving-away-from-one-disease-at-a-time-screening-trial-design-and-regulatory-implications-of-novel-platform-technologies
#5
JOURNAL ARTICLE
Julie Lekstrom-Himes, P J Brooks, Dwight D Koeberl, Amy Brower, Aaron Goldenberg, Robert C Green, Jill A Morris, Joseph J Orsini, Timothy W Yu, Erika F Augustine
Most rare diseases are caused by single-gene mutations, and as such, lend themselves to a host of new gene-targeted therapies and technologies including antisense oligonucleotides, phosphomorpholinos, small interfering RNAs, and a variety of gene delivery and gene editing systems. Early successes are encouraging, however, given the substantial number of distinct rare diseases, the ability to scale these successes will be unsustainable without new development efficiencies. Herein, we discuss the need for genomic newborn screening to match pace with the growing development of targeted therapeutics and ability to rapidly develop individualized therapies for rare variants...
February 4, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36734411/natural-history-of-mras-related-noonan-syndrome-evidence-of-mild-adult-onset-left-ventricular-hypertrophy-and-neuropsychiatric-features
#6
JOURNAL ARTICLE
Manuela Priolo, Cecilia Mancini, Francesca Clementina Radio, Luigi Chiriatti, Andrea Ciolfi, Camilla Cappelletti, Viviana Cordeddu, Letizia Pintomalli, Alfredo Brusco, Corrado Mammi, Marco Tartaglia
Gain of function pathogenic variants in MRAS have been found in a small subset of pediatric subjects presenting with Noonan syndrome (NS) associated with hypertrophic cardiomyopathy (HCM) and moderate to severe intellectual disability. These variants are considered to confer a high-risk for the development of severe HCM with poor prognosis and fatal outcome. We report on the natural history of the first adult subject with NS carrying the recurrent pathogenic p.Thr68Ile amino acid substitution. Different from what had previously been observed, he presented with a mild, late-onset left ventricular hypertrophy, and a constellation of additional symptoms rarely seen in NS...
February 3, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36691939/are-we-prepared-to-deliver-gene-targeted-therapies-for-rare-diseases
#7
JOURNAL ARTICLE
Timothy W Yu, Stephen F Kingsmore, Robert C Green, Tippi MacKenzie, Melissa Wasserstein, Michele Caggana, Nina B Gold, Annie Kennedy, Priya S Kishnani, Matthew Might, Phillip J Brooks, Jill A Morris, Melissa A Parisi, Tiina K Urv
The cost and time needed to conduct whole-genome sequencing (WGS) have decreased significantly in the last 20 years. At the same time, the number of conditions with a known molecular basis has steadily increased, as has the number of investigational new drug applications for novel gene-based therapeutics. The prospect of precision gene-targeted therapy for all seems in reach… or is it? Here we consider practical and strategic considerations that need to be addressed to establish a foundation for the early, effective, and equitable delivery of these treatments...
January 24, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36688577/gene-targeted-therapies-towards-equitable-development-diagnosis-and-access
#8
JOURNAL ARTICLE
Amy M Gaviglio, Mark W Skinner, Lily J Lou, Richard S Finkel, Erika F Augustine, Aaron J Goldenberg
Genomic and gene-targeted therapies hold great promise in addressing the global issue of rare diseases. To achieve this promise, however, it is critical the twin goals of equity in access to testing and diagnosis, and equity in access to therapy be considered early in the life cycle of development and implementation. Rare disease researchers and clinicians must simultaneously recognize the life-altering potential of early diagnosis and administration of gene-targeted therapeutics while acknowledging that not everyone who experiences a rare disease and needs these therapies will be able to afford or access them...
January 23, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36594517/data-sharing-to-advance-gene-targeted-therapies-in-rare-diseases
#9
JOURNAL ARTICLE
Julie Lekstrom-Himes, Erika F Augustine, Amy Brower, Thomas Defay, Richard S Finkel, Amy L McGuire, Mark W Skinner, Timothy W Yu
Recent advancements in gene-targeted therapies have highlighted the critical role data sharing plays in successful translational drug development for people with rare diseases. To scale these efforts, we need to systematize these sharing principles, creating opportunities for more rapid, efficient, and scalable drug discovery/testing including long-term and transparent assessment of clinical safety and efficacy. A number of challenges will need to be addressed, including the logistical difficulties of studying rare diseases affecting individuals who may be scattered across the globe, scientific, technical, regulatory, and ethical complexities of data collection, and harmonization and integration across multiple platforms and contexts...
January 3, 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36960570/note-from-the-editors
#10
JOURNAL ARTICLE
Tiina K Urv, Melissa A Parisi
No abstract text is available yet for this article.
March 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36876995/when-is-the-best-time-to-screen-and-evaluate-for-treatable-genetic-disorders-a-lifespan-perspective
#11
REVIEW
Melissa A Parisi, Michele Caggana, Jennifer L Cohen, Nina B Gold, Jill A Morris, Joseph J Orsini, Tiina K Urv, Melissa P Wasserstein
This paper focuses on the question of, "When is the best time to identify an individual at risk for a treatable genetic condition?" In this review, we describe a framework for considering the optimal timing for pursuing genetic and genomic screening for treatable genetic conditions incorporating a lifespan approach. Utilizing the concept of a carousel that represents the four broad time periods when critical decisions might be made around genetic diagnoses during a person's lifetime, we describe genetic testing during the prenatal period, the newborn period, childhood, and adulthood...
March 2023: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36541891/dermatological-manifestations-management-and-care-in-rasopathies
#12
REVIEW
Maria Ines Kavamura, Chiara Leoni, Giovanni Neri
RASopathies are rare genetic disorders caused by germline pathogenic variants in genes belonging to the RAS/MAPK pathway, which signals cell proliferation, differentiation, survival and death. The dysfunction of such signaling pathway causes syndromes with overlapping clinical manifestations. Skin and adnexal lesions are the cardinal clinical signs of RASopathies, such as cardiofaciocutaneous syndrome, Noonan syndrome with multiple lentigines, formerly known as LEOPARD syndrome, Costello syndrome, neurofibromatosis (NF1), Legius syndrome, Noonan-like syndrome with loose anagen hair (NSLH) and Noonan syndrome...
December 21, 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36533679/new-prospectives-on-treatment-opportunities-in-rasopathies
#13
REVIEW
Bruce D Gelb, Marielle E Yohe, Cordula Wolf, Gregor Andelfinger
The RASopathies are a group of clinically defined developmental syndromes caused by germline variants of the RAS/mitogen-activated protein (MAPK) cascade. The prototypic RASopathy is Noonan syndrome, which has phenotypic overlap with related disorders such as cardiofaciocutaneous syndrome, Costello syndrome, Noonan syndrome with multiple lentigines, and others. In this state-of-the-art review, we summarize current knowledge on unmet therapeutic needs in these diseases and novel treatment approaches informed by insights from RAS/MAPK-associated cancer therapies, in particular through inhibition of MEK1/2 and mTOR in patients with severe disease manifestations...
December 19, 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36515923/management-of-nutritional-and-gastrointestinal-issues-in-rasopathies-a-narrative-review
#14
REVIEW
Roberta Onesimo, Valentina Giorgio, Germana Viscogliosi, Elisabetta Sforza, Eliza Kuczynska, Gaia Margiotta, Mariella Iademarco, Francesco Proli, Donato Rigante, Giuseppe Zampino, Chiara Leoni
Noonan, Costello, and cardio-facio-cutaneous syndrome are neurodevelopmental disorders belonging to the RASopathies, a group of syndromes caused by alterations in the RAS/MAPK pathway. They are characterized by similar clinical features, among which feeding difficulties, growth delay, and gastro-intestinal disorders are frequent, causing pain and discomfort in patients. Hereby, we describe the main nutritional and gastrointestinal issues reported in individuals with RASopathies, specifically in Noonan syndrome, Noonan syndrome-related disorders, Costello, and cardio-facio-cutaneous syndromes...
December 14, 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36490374/neuropsychological-features-in-rasopathies-a-pilot-study-on-parent-training-program-involving-families-of-children-with-noonan-syndrome
#15
JOURNAL ARTICLE
Federica Alice Maria Montanaro, Paolo Alfieri, Cristina Caciolo, Francesca Cumbo, Simone Piga, Marco Tartaglia, Serena Licchelli, Maria Cristina Digilio, Stefano Vicari
Noonan syndrome (NS) is a clinical variable multisystem disorder caused by mutations in genes encoding proteins involved in the RAS/mitogen-activated protein kinase signaling pathway. NS is characterized by a distinctive facies, short stature, and congenital heart defects. Psychomotor delay, learning difficulties, and social deficits are also common. Furthermore, behavioral and attention problems can be reckoned as a key symptom in NS, with functioning resembling the patterns observed in attention deficit hyperactivity disorder (ADHD)...
December 9, 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36461161/bone-health-in-rasopathies
#16
REVIEW
David A Stevenson, Germana Viscogliosi, Chiara Leoni
The RASopathies are a group of disorders due to pathogenic variants in genes involved in the Ras/MAPK pathway, many of which have overlapping clinical features (e.g., neurofibromatosis type 1, Costello syndrome, cardiofaciocutaneous syndrome and Noonan syndrome) including musculoskeletal manifestations. Osteopenia and osteoporosis are reported in many of the RASopathies suggesting a shared pathogenesis. Even though osteopenia and osteoporosis are often detected and fractures have been reported, the clinical impact of bone mineralization defects on the skeleton of the various syndromes is poorly understood...
December 2, 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36461154/mosaic-rasopathies-a-review-of-disorders-caused-by-somatic-pathogenic-variants-in-the-genes-of-the-ras-mapk-pathway
#17
REVIEW
Diana Carli, Nicoletta Resta, Giovanni Battista Ferrero, Martino Ruggieri, Alessandro Mussa
Mosaic RASopathies are a heterogeneous group of diseases characterized by the presence at birth or early onset of congenital anomalies, cutaneous and vascular anomalies, segmental overgrowth, and increased cancer risk. They are caused by somatic pathogenic variants of the genes belonging the RAt Sarcoma Mitogen-activated protein kinase (RAS/MAPK) pathway causing its hyperactivation. Here, we review the clinical and molecular characteristics of this heterogeneous group of diseases, including the possibilities of molecular diagnosis and new therapeutic perspectives...
December 2, 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36541914/molecular-advances-clinical-management-and-treatment-opportunities-in-rasopathies
#18
JOURNAL ARTICLE
Chiara Leoni, Giovanni Neri
No abstract text is available yet for this article.
December 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36533693/cancer-incidence-and-surveillance-strategies-in-individuals-with-rasopathies
#19
REVIEW
Gina Ney, Andrea Gross, Alicia Livinski, Christian P Kratz, Douglas R Stewart
RASopathies are a set of clinical syndromes that have molecular and clinical overlap. Genetically, these syndromes are defined by germline pathogenic variants in RAS/MAPK pathway genes resulting in activation of this pathway. Clinically, their common molecular signature leads to comparable phenotypes, including cardiac anomalies, neurologic disorders and notably, elevated cancer risk. Cancer risk in individuals with RASopathies has been estimated from retrospective reviews and cohort studies. For example, in Costello syndrome, cancer incidence is significantly elevated over the general population, largely due to solid tumors...
December 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://read.qxmd.com/read/36454176/central-nervous-system-involvement-in-individuals-with-rasopathies
#20
REVIEW
K Nicole Weaver, Karen W Gripp
Central nervous system (CNS) anomalies are common in individuals with RASopathies. While certain findings, including relative or absolute macrocephaly, are typical for most RASopathies, other findings are more common in certain conditions, with rare low-grade gliomas in Noonan syndrome (NS); Chiari 1 malformation and tethered cord in Costello syndrome (CS); and variable structural anomalies including heterotopia and hydrocephalus in cardio-facio-cutaneous syndrome (CFC). We performed a literature review and present aggregate data on the common and uncommon CNS manifestations in individuals with RASopathies...
December 2022: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
journal
journal
40912
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.